46
Participants
Start Date
November 17, 2014
Primary Completion Date
January 22, 2018
Study Completion Date
January 22, 2018
BMS-986004 75 mg IV
BMS-986004 (75 mg) infusion (50 ml) administered in 120 minutes
BMS-986004 225 mg IV
BMS-986004 (225 mg) infusion (100 ml) administered in 120 minutes
BMS-986004 675 mg IV
BMS-986004 (675 mg) infusion (100 ml) administered in 120 minutes
BMS-986004 1500 mg IV
BMS-986004 (1500 mg) infusion (100 ml) administered in 120 minutes
Local Institution, Randwick
Local Institution, Brisbane
Georgetown University Medical Center, Washington D.C.
Emory University, Atlanta
Columbus Regional Research Institute, Columbus
Univ. Of Southern Calif. /Norris Comprehensive Cancer Center, Los Angeles
Local Institution, Saint Petersburg
Mass General Hospital, Boston
Rutgers- Robert Wood Johnson Medical School, New Brunswick
Hamilton Health Sciences/Mc Master Univ Med Ctre, Hamilton
Local Institution, Tbilisi
Local Institution, Chisinau
Oddzial Kliniczny Hematologii i Profilaktyki Chorob Nowotworowych, Chorzów
Specjalistyczny Gabinet Lekarski Prof. dr hab. Krzysztof Giannopoulos, Lublin
Local Institution, Warsaw
Local Institution, Smolensk
Local Institution, London
Local Institution, Manchester
Local Institution, Glasgow
Local Institution, London
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY